Stephen L. Rawlings

Array ( [id] => 12746572 [patent_doc_number] => 20180140691 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-24 [patent_title] => COMBINATION USE OF WT1 ANTIGEN PEPTIDE AND IMMUNOMODULATOR [patent_app_type] => utility [patent_app_number] => 15/575162 [patent_app_country] => US [patent_app_date] => 2016-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29188 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15575162 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12044590 [patent_doc_number] => 09822183 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-11-21 [patent_title] => 'CA6 antigen-specific cytotoxic conjugate and methods of using the same' [patent_app_type] => utility [patent_app_number] => 15/158510 [patent_app_country] => US [patent_app_date] => 2016-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 77 [patent_no_of_words] => 27621 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15158510 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12044590 [patent_doc_number] => 09822183 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-11-21 [patent_title] => 'CA6 antigen-specific cytotoxic conjugate and methods of using the same' [patent_app_type] => utility [patent_app_number] => 15/158510 [patent_app_country] => US [patent_app_date] => 2016-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 77 [patent_no_of_words] => 27621 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15158510 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12044590 [patent_doc_number] => 09822183 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-11-21 [patent_title] => 'CA6 antigen-specific cytotoxic conjugate and methods of using the same' [patent_app_type] => utility [patent_app_number] => 15/158510 [patent_app_country] => US [patent_app_date] => 2016-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 77 [patent_no_of_words] => 27621 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15158510 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17178380 [patent_doc_number] => 11155615 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-26 [patent_title] => Anti-ROR1 antibodies [patent_app_type] => utility [patent_app_number] => 15/574810 [patent_app_country] => US [patent_app_date] => 2016-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 44 [patent_no_of_words] => 22773 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15574810 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11129258 [patent_doc_number] => 20160326232 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-10 [patent_title] => 'Prostate Specific Membrane Antigen Binding Fibronectin Type III Domains' [patent_app_type] => utility [patent_app_number] => 15/148312 [patent_app_country] => US [patent_app_date] => 2016-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 26616 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15148312 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16460787 [patent_doc_number] => 10844122 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-24 [patent_title] => Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof [patent_app_type] => utility [patent_app_number] => 15/148371 [patent_app_country] => US [patent_app_date] => 2016-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 31546 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15148371 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12165339 [patent_doc_number] => 09884098 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-02-06 [patent_title] => 'Multivalent breast cancer vaccine' [patent_app_type] => utility [patent_app_number] => 15/144372 [patent_app_country] => US [patent_app_date] => 2016-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 10144 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15144372 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11107621 [patent_doc_number] => 20160304592 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-20 [patent_title] => 'SPARC BINDING SCFVS' [patent_app_type] => utility [patent_app_number] => 15/132647 [patent_app_country] => US [patent_app_date] => 2016-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 17541 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15132647 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12624588 [patent_doc_number] => 20180100026 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-12 [patent_title] => OPTIMIZED CHIMERIC RECEPTOR T CELL SWITCHES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/566685 [patent_app_country] => US [patent_app_date] => 2016-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 71328 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -103 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15566685 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11025159 [patent_doc_number] => 20160222114 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-04 [patent_title] => 'FULLY HUMAN ANTIBODIES TO BTLA' [patent_app_type] => utility [patent_app_number] => 15/098627 [patent_app_country] => US [patent_app_date] => 2016-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 37617 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15098627 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12676024 [patent_doc_number] => 20180117174 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-03 [patent_title] => DRUG CONJUGATES COMPRISING ANTIBODIES AGAINST CLAUDIN 18.2 [patent_app_type] => utility [patent_app_number] => 15/565848 [patent_app_country] => US [patent_app_date] => 2016-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34865 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -66 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15565848 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11310259 [patent_doc_number] => 20160346369 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-01 [patent_title] => 'Epidermal Growth Factor Receptor Variant III-Mesothelin Fusions and Methods of Using the Same' [patent_app_type] => utility [patent_app_number] => 15/097178 [patent_app_country] => US [patent_app_date] => 2016-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 21512 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15097178 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12241194 [patent_doc_number] => 20180074058 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-15 [patent_title] => 'Methods of Determining Patient Populations Amenable to Immunomodulatory Treatment of Cancer' [patent_app_type] => utility [patent_app_number] => 15/564704 [patent_app_country] => US [patent_app_date] => 2016-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 15321 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 18 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15564704 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13858681 [patent_doc_number] => 10191057 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-01-29 [patent_title] => Methods of diagnosing, classifying and treating endometrial cancer and precancer [patent_app_type] => utility [patent_app_number] => 15/088099 [patent_app_country] => US [patent_app_date] => 2016-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 18 [patent_no_of_words] => 18286 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 326 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15088099 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11053364 [patent_doc_number] => 20160250327 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-01 [patent_title] => 'METHODS AND COMPOSITIONS TO REDUCE LIVER DAMAGE ASSOCIATED WITH CONDITIONS OR THERAPIES THAT AFFECT THE IMMUNE SYSTEM' [patent_app_type] => utility [patent_app_number] => 15/082898 [patent_app_country] => US [patent_app_date] => 2016-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 8873 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15082898 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11082252 [patent_doc_number] => 20160279216 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-29 [patent_title] => 'NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS' [patent_app_type] => utility [patent_app_number] => 15/082978 [patent_app_country] => US [patent_app_date] => 2016-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 45627 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15082978 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12240127 [patent_doc_number] => 20180072990 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-15 [patent_title] => 'GENERATING VIRUS OR OTHER ANTIGEN-SPECIFIC T CELLS FROM A NAÏVE T CELL POPULATION' [patent_app_type] => utility [patent_app_number] => 15/563854 [patent_app_country] => US [patent_app_date] => 2016-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 6306 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15563854 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11689621 [patent_doc_number] => 20170165335 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-15 [patent_title] => 'NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PANCREATIC CANCER AND OTHER CANCERS' [patent_app_type] => utility [patent_app_number] => 15/073528 [patent_app_country] => US [patent_app_date] => 2016-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 42607 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15073528 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11129288 [patent_doc_number] => 20160326264 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-10 [patent_title] => 'ANTIBODY THERAPEUTICS THAT BIND PSMA' [patent_app_type] => utility [patent_app_number] => 15/066806 [patent_app_country] => US [patent_app_date] => 2016-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 23461 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15066806 [rel_patent_id] =>[rel_patent_doc_number] =>)